[go: up one dir, main page]

PE20060084A1 - Hidrocloruro de [4-(5-(aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos - Google Patents

Hidrocloruro de [4-(5-(aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos

Info

Publication number
PE20060084A1
PE20060084A1 PE2005000325A PE2005000325A PE20060084A1 PE 20060084 A1 PE20060084 A1 PE 20060084A1 PE 2005000325 A PE2005000325 A PE 2005000325A PE 2005000325 A PE2005000325 A PE 2005000325A PE 20060084 A1 PE20060084 A1 PE 20060084A1
Authority
PE
Peru
Prior art keywords
tryptase
inhibitor
thiofen
cyt
piperidin
Prior art date
Application number
PE2005000325A
Other languages
English (en)
Inventor
Zhongli Gao
Larry Davis
Mark Czekaj
Adam W Sledeski
Julian Levell
El-Bdaoui Haddad
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of PE20060084A1 publication Critical patent/PE20060084A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE DICHO COMPUESTO ES INHIBIDOR DE TRIPTASA, UTILES EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS, AFECCIONES FIBROTICAS, CONJUNTIVITIS, ARTRITIS, ENFERMEDAD PERIODONTAL, RETINOPATIA DIABETICA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA EN COMBINACION CON UN COMPUESTO SELECCIONADO ENTRE AGONISTA BETA ADRENERGICO, ANTICOLINERGICO, CORTICOSTEROIDE ANTIINFLAMATORIO Y UN VEHICULO FARMACEUTICAMENTE ACEPTABLE
PE2005000325A 2004-03-26 2005-03-22 Hidrocloruro de [4-(5-(aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos PE20060084A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55692704P 2004-03-26 2004-03-26

Publications (1)

Publication Number Publication Date
PE20060084A1 true PE20060084A1 (es) 2006-03-09

Family

ID=34964263

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000325A PE20060084A1 (es) 2004-03-26 2005-03-22 Hidrocloruro de [4-(5-(aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos

Country Status (25)

Country Link
US (1) US20070142435A1 (es)
EP (1) EP1737848A1 (es)
JP (1) JP2007530580A (es)
KR (1) KR20060130682A (es)
CN (1) CN1956978A (es)
AR (1) AR048336A1 (es)
AU (1) AU2005230934A1 (es)
BR (1) BRPI0509245A (es)
CA (1) CA2560649A1 (es)
CR (1) CR8603A (es)
DO (1) DOP2005000039A (es)
EC (1) ECSP066878A (es)
IL (1) IL178031A0 (es)
MA (1) MA28547B1 (es)
MX (1) MXPA06010610A (es)
NO (1) NO20064811L (es)
PA (1) PA8627601A1 (es)
PE (1) PE20060084A1 (es)
RU (1) RU2330034C1 (es)
TN (1) TNSN06278A1 (es)
TW (1) TW200602035A (es)
UA (1) UA83738C2 (es)
UY (1) UY28821A1 (es)
WO (1) WO2005097780A1 (es)
ZA (1) ZA200607752B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20071148A1 (es) * 2006-03-29 2007-12-10 Sanofi Aventis Mejoras en la preparacion de intermedios que conducen a hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona
AR065616A1 (es) * 2007-03-07 2009-06-17 Sanofi Aventis Sintesis regioselectiva de ullmann de acido 4- bromo-3- metil-5- propoxi- tiofeno-2- carboxilico
WO2008115912A1 (en) * 2007-03-21 2008-09-25 Sanofi-Aventis Regio-specific synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid
AR065858A1 (es) * 2007-03-29 2009-07-08 Sanofi Aventis Metodo para preparar el inhibidor de triptasa [ 4-(5-aminoetil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona.
WO2008121669A1 (en) * 2007-03-29 2008-10-09 Sanofi-Aventis 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester, its regio-specific synthesis and intermediate thereto
WO2009067202A1 (en) 2007-11-21 2009-05-28 Janssen Pharmaceutica, N.V. Spiropiperidines for use as tryptase inhibitors
WO2009094641A2 (en) * 2008-01-24 2009-07-30 Dor Biopharma, Inc. Topically active steroids for use in interstitial pulmonary fibrosis
RU2509766C2 (ru) * 2008-08-22 2014-03-20 Санофи-Авентис [4-(5-аминометил-2-фторфенил)-пиперидин-1-ил]-[7-фтор-1-(2-метоксиэтил)-4-трифторметокси-1н-индол-3-ил]-метанон как ингибитор триптазы тучных клеток
TW201034675A (en) 2008-12-18 2010-10-01 Sanofi Aventis Method for treating macular degeneration
FR2955324A1 (fr) * 2010-01-15 2011-07-22 Sanofi Aventis [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
EP2483243B1 (en) 2009-09-24 2015-03-18 Sanofi-Aventis U.S. LLC Synthesis of (4-fluoro-3-piperidin-4-yl-benzyl)-carbamic acid tert-butyl ester and intermediates thereof
EP2516428A1 (en) * 2009-12-23 2012-10-31 Sanofi Tropinone benzylamines as beta-tryptase inhibitors
JP2013515723A (ja) * 2009-12-23 2013-05-09 サノフイ 炎症性腸疾患の処置
SG181504A1 (en) * 2009-12-23 2012-07-30 Sanofi Sa Indolyl-piperidinyl benzylamines as beta-tryptase inhibitors
AR080255A1 (es) * 2010-02-24 2012-03-21 Sanofi Aventis Tratamiento de afecciones alergicas dermatologicas. composicion farmaceutica
EA025662B1 (ru) 2011-10-07 2017-01-30 Такеда Фармасьютикал Компани Лимитед 1-арилкарбонил-4-оксипиперидиновые соединения, полезные для лечения нейродегенеративных заболеваний
CN116715775A (zh) * 2017-02-10 2023-09-08 豪夫迈·罗氏有限公司 抗类胰蛋白酶抗体、其组合物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3347A1 (fr) * 2000-05-22 2001-11-29 Aventis Pharma Inc Dérivés d'arylméthylamine pour leur utilisation comme inhibiteurs de la tryptase
GB0012362D0 (en) * 2000-05-22 2000-07-12 Aventis Pharma Ltd Chemical compounds

Also Published As

Publication number Publication date
CA2560649A1 (en) 2005-10-20
UA83738C2 (en) 2008-08-11
BRPI0509245A (pt) 2007-09-11
NO20064811L (no) 2006-10-23
AU2005230934A1 (en) 2005-10-20
TW200602035A (en) 2006-01-16
PA8627601A1 (es) 2006-01-23
US20070142435A1 (en) 2007-06-21
MXPA06010610A (es) 2006-12-15
UY28821A1 (es) 2005-10-31
TNSN06278A1 (en) 2007-12-03
ECSP066878A (es) 2006-11-24
ZA200607752B (en) 2008-05-28
JP2007530580A (ja) 2007-11-01
MA28547B1 (fr) 2007-04-03
DOP2005000039A (es) 2005-10-31
CN1956978A (zh) 2007-05-02
AR048336A1 (es) 2006-04-19
CR8603A (es) 2007-06-08
EP1737848A1 (en) 2007-01-03
RU2006137717A (ru) 2008-05-10
RU2330034C1 (ru) 2008-07-27
KR20060130682A (ko) 2006-12-19
WO2005097780A1 (en) 2005-10-20
IL178031A0 (en) 2006-12-31

Similar Documents

Publication Publication Date Title
PE20060084A1 (es) Hidrocloruro de [4-(5-(aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
CR11683A (es) Piridinas y pirazinas como inhibidores de p13k
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
PE20090511A1 (es) Imidazopiridinonas
PE20070833A1 (es) Compuestos de pirimidinil benzotiofeno
PE20081341A1 (es) Inhibidores de la actividad de la akt
ATE446962T1 (de) Thiazolopyridinon-derivate als mch- rezeptorantagonisten
PE20061439A1 (es) DERIVADOS DE 2-AMIDO-6-AMINO-8-OXO-PURINA COMO MODULADORES DEL RECEPTOR Toll (TLR)
UY29938A1 (es) Derivados de pirido-, pirazo- y pirimido-pirimidina y su uso como inhibidores de mtor
CO5640076A2 (es) Composicion farmaceutica que comprende un inhibidor de ibat para el tratamiento o profilaxis del estreñimiento
WO2008012622A3 (en) Azabenzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
CR20110093A (es) [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos
CO6270285A2 (es) Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida
PE20060937A1 (es) Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2)
PE20140858A1 (es) Derivados de piperidina como inhibidores de renina
PE20080338A1 (es) 4-[5-(2-amino-etansulfonil)-isoquinolin-7-il]-fenol como inhibidor de akt (proteina cinasa)
MX2010002584A (es) Derivados de piperidina como agonistas de receptores muscarinicos.
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
CL2007002899A1 (es) Compuestos derivados de azaciclilaminas n-sustituidas, inhibidores del receptor de histamina 3; proceso de preparacion; composicion farmaceutica que comprende los compuestos, y usopara el tratamiento de trastornos cognitivos, esquizofre nia y enfermedad de alzheimer entre otros.
PE20060589A1 (es) FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b
DK1828177T3 (da) Hidtil ukendte MCH-receptorantagonister
PE20060176A1 (es) Antagonistas de cgrp seleccionados, procedimientos para su preparacion, y su empleo como medicamentos
ECSP088781A (es) Derivados de benzimidazol
AR058904A1 (es) Proceso mejorado para la preparacion de un derivado de 5h-pirrolo[3,4-b] pirazina opticamente activo
EA201070916A1 (ru) Двойные фармакофоры - pde4-мускариновые антагонисты

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed